
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5077608/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Expression of the transient receptor potential vanilloid 1 (TRPV1) in LNCaP and PC-3 prostate cancer cells and in human prostate tissue. European Journal of Pharmacology, 2005, 515, 20-27.	3.5	114
2	VIP and PACAP are autocrine factors that protect the androgen-independent prostate cancer cell line PC-3 from apoptosis induced by serum withdrawal. British Journal of Pharmacology, 2003, 139, 1050-1058.	5.4	57
3	Nuclear localization of vasoactive intestinal peptide (VIP) receptors in human breast cancer. Peptides, 2010, 31, 2035-2045.	2.4	51
4	Vasoactive intestinal peptide (VIP) induces transactivation of EGFR and HER2 in human breast cancer cells. Molecular and Cellular Endocrinology, 2009, 302, 41-48.	3.2	50
5	Receptors for vasoactive intestinal peptide on isolated epithelial cells of rat ventral prostate. Biochimica Et Biophysica Acta - Molecular Cell Research, 1983, 763, 408-413.	4.1	45
6	Vasoactive intestinal peptide induces neuroendocrine differentiation in the LNCaP prostate cancer cell line through PKA, ERK, and PI3K. Prostate, 2005, 63, 44-55.	2.3	45
7	Vasoactive intestinal peptide increases vascular endothelial growth factor expression and neuroendocrine differentiation in human prostate cancer LNCaP cells. Regulatory Peptides, 2004, 119, 69-75.	1.9	41
8	Cyclic AMP-stimulating effect of vasoactive intestinal peptide in isolated epithelial cells of rat ventral prostate. Biochimica Et Biophysica Acta - Molecular Cell Research, 1983, 763, 414-418.	4.1	40
9	Vasoactive intestinal peptide (VIP) induces c-fos expression in LNCaP prostate cancer cells through a mechanism that involves Ca2+ signalling. Implications in angiogenesis and neuroendocrine differentiation. Biochimica Et Biophysica Acta - Molecular Cell Research, 2005, 1744, 224-233.	4.1	37
10	Neuroendocrine differentiation of the LNCaP prostate cancer cell line maintains the expression and function of VIP and PACAP receptors. Cellular Signalling, 2001, 13, 887-894.	3.6	36
11	Vasoactive intestinal peptide enhances growth and angiogenesis of human experimental prostate cancer in a xenograft model. Peptides, 2007, 28, 1896-1901.	2.4	30
12	In vitro antitumor and hypotensive activity of peptides from olive seeds. Journal of Functional Foods, 2018, 42, 177-184.	3.4	30
13	Vasoactive intestinal peptide (VIP) increases vascular endothelial growth factor (VEGF) expression and secretion in human breast cancer cells. Regulatory Peptides, 2007, 144, 101-108.	1.9	29
14	Vasoactive intestinal peptide (VIP) induces malignant transformation of the human prostate epithelial cell line RWPE-1. Cancer Letters, 2010, 299, 11-21.	7.2	29
15	RNA interference-directed silencing of VPAC1 receptor inhibits VIP effects on both EGFR and HER2 transactivation and VEGF secretion in human breast cancer cells. Molecular and Cellular Endocrinology, 2012, 348, 241-246.	3.2	29
16	Vasoactive intestinal peptide behaves as a proâ€metastatic factor in human prostate cancer cells. Prostate, 2009, 69, 774-786.	2.3	27
17	PACAP expression and distribution in human breast cancer and healthy tissue. Cancer Letters, 2004, 205, 189-195.	7.2	26
18	Expression of functionally active cannabinoid receptor CB1in the human prostate gland. Prostate, 2003, 54, 95-102.	2.3	24

#	Article	IF	CITATIONS
19	Pituitary adenylate cyclase-activating peptide/vasoactive intestinal peptide receptors in human normal mammary gland and breast cancer tissue. Gynecological Endocrinology, 2005, 20, 327-333.	1.7	24
20	Vasoactive intestinal peptide (VIP) inhibits human renal cell carcinoma proliferation. Biochimica Et Biophysica Acta - Molecular Cell Research, 2012, 1823, 1676-1685.	4.1	24
21	Ontogeny of vasoactive intestinal peptide receptors in rat ventral prostate. General Pharmacology, 1994, 25, 509-514.	0.7	22
22	Expression of functional PACAP/VIP receptors in human prostate cancer and healthy tissue. Peptides, 2003, 24, 893-902.	2.4	22
23	Hypoxia regulation of expression and angiogenic effects of vasoactive intestinal peptide (VIP) and VIP receptors in LNCaP prostate cancer cells. Molecular and Cellular Endocrinology, 2006, 249, 116-122.	3.2	22
24	Multifunctional role of VIP in prostate cancer progression in a xenograft model: Suppression by curcumin and COX-2 inhibitor NS-398. Peptides, 2009, 30, 2357-2364.	2.4	21
25	Influence of castration and testosterone treatment on the vasoactive intestinal peptide receptor/effector system in rat prostatic epithelial cells. Biochimica Et Biophysica Acta - Molecular Cell Research, 1988, 969, 86-90.	4.1	20
26	Identification and Functional Properties of the Pituitary Adenylate Cyclase Activating Peptide (PAC1) Receptor in Human Benign Hyperplastic Prostate. Cellular Signalling, 1999, 11, 813-819.	3.6	19
27	Vasoactive intestinal peptide induces cyclooxygenase-2 expression through nuclear factor-κB in human prostate cell lines. Molecular and Cellular Endocrinology, 2007, 270, 8-16.	3.2	19
28	Inhibitory effects of antagonists of growth hormoneâ€releasing hormone on growth and invasiveness of PC3 human prostate cancer. International Journal of Cancer, 2013, 132, 755-765.	5.1	18
29	Overexpression of vasoactive intestinal peptide receptors and cyclooxygenase-2 in human prostate cancer. Analysis of potential prognostic relevance. Histology and Histopathology, 2012, 27, 1093-101.	0.7	18
30	Characterization of insulin receptors in isolated epithelial cells of rat ventral prostate: Effect of fasting. Cell Biochemistry and Function, 1986, 4, 19-24.	2.9	17
31	Regulation of HER expression and transactivation in human prostate cancer cells by a targeted cytotoxic bombesin analog (ANâ€215) and a bombesin antagonist (RCâ€3095). International Journal of Cancer, 2010, 127, 1813-1822.	5.1	17
32	In vitro and in vivo evaluation of first-generation carbosilane arene Ru(II)-metallodendrimers in advanced prostate cancer. European Polymer Journal, 2019, 113, 229-235.	5.4	17
33	Cyclic AMP response to vasoactive intestinal peptide and β-adrenergic or cholinergic agonists in isolated epithelial cells of rat ventral prostate. Bioscience Reports, 1985, 5, 791-797.	2.4	16
34	Expression and distribution of pituitary adenylate cyclase-activating peptide in human prostate and prostate cancer tissues. Regulatory Peptides, 2002, 110, 9-15.	1.9	16
35	Antioxidant activity of vasoactive intestinal peptide in HK2 human renal cells. Peptides, 2012, 38, 275-281.	2.4	16
36	Growth hormone-releasing hormone (GHRH) promotes metastatic phenotypes through EGFR/HER2 transactivation in prostate cancer cells. Molecular and Cellular Endocrinology, 2017, 446, 59-69.	3.2	16

#	Article	IF	CITATIONS
37	Characterization of vasoactive intestinal peptide/pituitary adenylate cyclase-activating peptide receptors in human benign hyperplastic prostate. Endocrinology, 1996, 137, 2815-2822.	2.8	16
38	Protein kinase c regulation of the adenylyl cyclase system in rat prostatic epithelium. Prostate, 1995, 27, 204-211.	2.3	15
39	G-proteins and β-adrenergic stimulation of adenylate cyclase activity in the diabetic rat prostate. , 1997, 33, 46-54.		15
40	Growth hormone-releasing hormone antagonists abolish the transactivation of human epidermal growth factor receptors in advanced prostate cancer models. Investigational New Drugs, 2014, 32, 871-882.	2.6	15
41	Vip binding to epithelial cell membranes of rat ventral prostate: Effect of guanine nucleotides. General Pharmacology, 1985, 16, 495-500.	0.7	14
42	Effects of age and androgens upon functional vasoactive intestinal peptide receptors in rat prostatic epithelial cells. Biochimica Et Biophysica Acta - Molecular Cell Research, 1986, 888, 338-343.	4.1	14
43	Effect of lindane upon the β-adrenergic stimulation of cyclic AMP accumulation in rat renal cortical tubules caused by alterations in membrane fluidity. Life Sciences, 1991, 49, 1141-1154.	4.3	14
44	Vasoactive intestinal peptide induces oxidative stress and suppresses metastatic potential in human clear cell renal cell carcinoma. Molecular and Cellular Endocrinology, 2013, 365, 212-222.	3.2	14
45	Anticancer Activity of Dendriplexes against Advanced Prostate Cancer from Protumoral Peptides and Cationic Carbosilane Dendrimers. Biomacromolecules, 2019, 20, 1224-1234.	5.4	14
46	Alteration of Protein Kinase C Activity in Diabetic Rat Prostate. Biochemical and Biophysical Research Communications, 1993, 195, 166-172.	2.1	13
47	VIP induces NF-κB1-nuclear localisation through different signalling pathways in human tumour and non-tumour prostate cells. Cellular Signalling, 2015, 27, 236-244.	3.6	13
48	Antitumoral effects of vasoactive intestinal peptide in human renal cell carcinoma xenografts in athymic nude mice. Cancer Letters, 2013, 336, 196-203.	7.2	12
49	Regulation of the expression of protein kinase C isoenzymes in rat ventral prostate: effects of age, castration and flutamide treatment. Life Sciences, 2002, 71, 2257-2266.	4.3	11
50	Expression of vasoactive intestinal peptide and functional VIP receptors in human prostate cancer: Antagonistic action of a growth-hormone-releasing hormone analog. International Journal of Oncology, 2005, 26, 1629-35.	3.3	11
51	Somatostatin inhibits VIP- and isoproterenol-stimulated cyclic AMP accumulation in rat prostatic epithelial cells. FEBS Letters, 1987, 218, 73-76.	2.8	10
52	Modulation of the β-adrenergic stimulation of cyclic AMP accumulation in rat prostatic epithelial cells by membrane fluidity. General Pharmacology, 1990, 21, 931-933.	0.7	10
53	Cholesterol modulation of membrane fluidity and VIP receptor/effector system in rat prostatic epithelial cells. Regulatory Peptides, 1991, 33, 287-297.	1.9	10
54	Neuropeptide Y inhibits vasoactive intestinal peptide-stimulated adenylyl cyclase in rat ventral prostate. Neuropeptides, 1994, 27, 31-37.	2.2	10

#	Article	IF	CITATIONS
55	Protein kinase C isozymes in prostatic epithelial cells from normal, diabetic and insulin-treated diabetic rats. General Pharmacology, 1995, 26, 1673-1678.	0.7	10
56	Effect of flutamide-induced androgen-receptor blockade on adenylate cyclase activation through G-protein coupled receptors in rat prostate. Cellular Signalling, 2000, 12, 311-316.	3.6	10
57	Growth hormoneâ€releasing hormone receptor antagonists modify molecular machinery in the progression of prostate cancer. Prostate, 2018, 78, 915-926.	2.3	10
58	Stimulation of neuroendocrine differentiation in prostate cancer cells by GHRH and its blockade by GHRH antagonists. Investigational New Drugs, 2020, 38, 746-754.	2.6	10
59	5-Hydroxytryptamine1A Receptor-Mediated Effects on Adenylate Cyclase and Nitric Oxide Synthase Activities in Rat Ventral Prostate. Cellular Signalling, 1998, 10, 583-587.	3.6	9
60	LOW EXPRESSION OF \hat{G}_{\pm} PROTEIN SUBUNITS IN HUMAN PROSTATE CANCER. Journal of Urology, 2001, 166, 2512-2517.	0.4	9
61	Effects of the Antiandrogen Flutamide on the Expression of Protein Kinase C Isoenzymes in LNCaP and PC3 Human Prostate Cancer Cells. Bioscience Reports, 2004, 24, 11-21.	2.4	9
62	Tumor-promoting phorbol esters interfere with the vasoactive intestinal peptide receptor/effector system in rat prostatic epithelial cells. Biochemical and Biophysical Research Communications, 1987, 149, 221-226.	2.1	8
63	Growth hormone binding and stimulation of amino acid uptake in epithelial cells of rat ventral prostate. Cell Biochemistry and Function, 1987, 5, 63-68.	2.9	8
64	β-Adrenergic stimulation of cyclic AMP accumulation in rat prostatic epithelial cells during sexual maturation. Mechanisms of Ageing and Development, 1990, 52, 79-86.	4.6	8
65	Anti-proliferative and pro-apoptotic effects of GHRH antagonists in prostate cancer. Oncotarget, 2016, 7, 52195-52206.	1.8	8
66	Characterization and age dependence of the stimulatory effect of VIP on cyclic AMP accumulation in rat Leydig cells. Bioscience Reports, 1987, 7, 805-811.	2.4	7
67	Heterofunctional ruthenium(II) carbosilane dendrons, a new class of dendritic molecules to fight against prostate cancer. European Journal of Medicinal Chemistry, 2020, 207, 112695.	5.5	7
68	In vitro age-dependent incorporation of [1-14C]acetate into lipid subclasses in rat ventral prostate. International Journal of Biochemistry & Cell Biology, 1985, 17, 1129-1132.	0.5	6
69	Lindane inhibits β-adrenergic stimulation of cyclic AMP accumulation in rat prostatic epithelial cells. Pesticide Biochemistry and Physiology, 1990, 38, 197-203.	3.6	6
70	Effects ofPygeum africanum extract (Tadenan�) on vasoactive intestinal peptide receptors, G proteins, and adenylyl cyclase in rat ventral prostate. Prostate, 2000, 45, 245-252.	2.3	6
71	Growth hormone-releasing hormone induced transactivation of epidermal growth factor receptor in human triple-negative breast cancer cells. Peptides, 2016, 86, 153-161.	2.4	6
72	Differential effect of arachidonic acid on the vasoactive intestinal peptide receptor/effector system in rat prostatic epithelium during sexual maturation. Peptides, 1992, 13, 1117-1122.	2.4	5

#	Article	IF	CITATIONS
73	Characterization of protein kinase C in rat and human prostates. Bioscience Reports, 1993, 13, 313-323.	2.4	5
74	Signalling pathways involved in antitumoral effects of VIP in human renal cell carcinoma A498 cells: VIP induction of p53 expression. International Journal of Biochemistry and Cell Biology, 2014, 53, 295-301.	2.8	5
75	The effect of streptozotocin diabetes on the vasoactive intestinal peptide receptor/effector system in membranes from rat ventral prostate. Endocrinology, 1992, 131, 1993-1998.	2.8	5
76	Transactivation of HER2 by vasoactive intestinal peptide in experimental prostate cancer: Antagonistic action of an analog of growth-hormone-releasing hormone. International Journal of Oncology, 2007, 31, 1223-30.	3.3	5
77	[1-14C]acetate incorporation into free and esterified cholesterol during the development of the rat ventral prostate. Comparative Biochemistry and Physiology Part B: Comparative Biochemistry, 1984, 79, 633-636.	0.2	3
78	Tissue and plasma distribution of exogenous growth hormone-releasing factor analogue (GRF1-29NH2) after intravenous, subcutaneous and intraperitoneal injection in the rat. General Pharmacology, 1987, 18, 551-554.	0.7	3
79	Effect of gastroduodenostomy on intestinal vasoactive intestinal peptide (VIP) levels, and VIP binding and VIP stimulation of cyclic AMP in intestinal epithelial cells from rat. Biochemical Medicine and Metabolic Biology, 1987, 37, 307-313.	0.7	3
80	Receptors for tumor-promoting phorbol esters in rat ventral prostate. Cancer Letters, 1993, 68, 143-147.	7.2	3
81	Ontogenic Development of the Adenylyl Cyclase Enzyme and the αs, αi1 and αi2 G-protein Regulatory Subunits from Rat Prostate. Cellular Signalling, 1997, 9, 451-456.	3.6	3
82	Effects of the luteinising hormone-releasing hormone (LH-RH) agonist leuprolide on adenylyl cyclase regulation through G-protein coupled receptors in rat ventral prostate. European Journal of Cancer, 2001, 37, 641-648.	2.8	3
83	Tumorigenic transformation of human prostatic epithelial cell line RWPEâ€1 by growth hormoneâ€releasing hormone (GHRH). Prostate, 2022, 82, 933-941.	2.3	3
84	Up-modulation of phorbol dibutyrate receptors by carbachol and arachidonic acid in rat prostatic epithelial cells. Bioscience Reports, 1991, 11, 189-194.	2.4	2
85	Uncoupling of VIP receptor/effector system in rat prostatic epithelium by increasing cell membrane rigidity. Regulatory Peptides, 1989, 26, 176.	1.9	Ο